Cost-Effectiveness of Biologics for Allergic Diseases

被引：23

作者：

Wu, Ann Chen ^{[1
,2
]}

Fuhlbrigge, Anne L. ^{[3
]}

Robayo, Maria Acosta ^{[1
,2
]}

Shaker, Marcus ^{[4
,5
,6
,7
]}

机构：

[1] Harvard Med Sch, Ctr Healthcare Res Pediat, Dept Populat Med, Boston, MA USA

[2] Harvard Pilgrim Hlth Care Inst, Boston, MA USA

[3] Univ Colorado, Sch Med, Pulm Sci & Crit Care Med, Dept Med, Aurora, CO USA

[4] Dartmouth Hitchcock Med Ctr, Sect Allergy & Immunol, Lebanon, NH 03766 USA

[5] Geisel Sch Med Dartmouth, Dept Pediat, Hanover, NH USA

[6] Geisel Sch Med Dartmouth, Dept Med, Hanover, NH USA

[7] Geisel Sch Med Dartmouth, Dept Community & Family Med, Hanover, NH USA

来源：

JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY-IN PRACTICE | 2021年 / 9卷 / 03期

关键词：

Biologics; Monoclonal antibodies; mAbs; Cost-effectiveness; Allergic disease; ANTI-IGE ANTIBODY; JOINT TASK-FORCE; QUALITY-OF-LIFE; ANTI-IL-5 MEPOLIZUMAB THERAPY; ANTIIMMUNOGLOBULIN-E ANTIBODY; CHRONIC SPONTANEOUS URTICARIA; LONG-TERM CONTROL; MONOCLONAL-ANTIBODY; SEVERE ASTHMA; IMMUNOLOGY/AMERICAN-COLLEGE;

D O I：

10.1016/j.jaip.2020.10.009

中图分类号：

R392 [医学免疫学];

学科分类号：

100102 ;

摘要：

The introduction of specific humanized monoclonal antibodies over the past 20 years has dramatically changed the treatment of allergic diseases. At present, 5 mAbs are licensed for treating moderate to severe allergic and eosinophilic asthma, atopic dermatitis, chronic spontaneous urticaria, chronic sinusitis with nasal polyps, and eosinophilic granulomatosis with polyangiitis. Given the high costs of biologics, understanding their cost-effectiveness is critical. As new biologics are developed and new indications are approved for existing biologics, the use of biologics for allergic diseases will increase. Conducting cost-effectiveness evaluations in parallel to efficacy and effectiveness trials will help patients, providers, payers, and policymakers in decision making. (C) 2020 American Academy of Allergy, Asthma & Immunology

引用

页码：1107 / +

页数：13

共 106 条

[21] Relationship Between Benralizumab Exposure and Efficacy for Patients With Severe Eosinophilic Asthma
Chia, Yen Lin
Yan, Li
Yu, Binbing
Wang, Bing
Barker, Peter
Goldman, Mitchell
Roskos, Lorin
[J]. CLINICAL PHARMACOLOGY & THERAPEUTICS, 2019, 106 (02) : 383 - 390
[22] Choy Min Sung, 2016, P T, V41, P619
[23] Rapid onset of effect of benralizumab on morning peak expiratory flow in severe, uncontrolled asthma
Chupp, Geoffrey
Lugogo, Njira L.
Kline, Joel N.
Ferguson, Gary T.
Hirsch, Ian
Goldman, Mitchell
Zangrilli, James G.
Trudo, Frank
[J]. ANNALS OF ALLERGY ASTHMA & IMMUNOLOGY, 2019, 122 (05) : 478 - 485
[24] CINQAIR, RESL INJ
[25] ClinicalTrials.gov, SEARCH BENR COMPL ST
[26] ClinicalTrials.gov, SEARCH MEP COMPL STU
[27] ClinicalTrials.gov, STUD EV EFF SAF RES
[28] Omalizumab, a recombinant humanized anti-IgE antibody, reduces asthma-related emergency room visits and hospitalizations in patients with allergic asthma
Corren, J
Casale, T
Deniz, Y
Ashby, M
[J]. JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2003, 111 (01) : 87 - 90
[29] Phase 3 Study of Reslizumab in Patients With Poorly Controlled Asthma Effects Across a Broad Range of Eosinophil Counts
Corren, Jonathan
Weinstein, Steven
Janka, Lindsay
Zangrilli, James
Garin, Margaret
[J]. CHEST, 2016, 150 (04) : 799 - 810
[30] American Academy of Allergy, Asthma & Immunology/American College of Allergy, Asthma and Immunology joint task force report on omalizumab-associated anaphylaxis
Cox, Linda
Platts-Mills, Thomas A. E.
Finegold, Ira
Schwartz, Lawrence B.
Simons, F. Estelle R.
Wallace, Dana V.
[J]. JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2007, 120 (06) : 1373 - 1377

← 1 2 3 4 5 6 7 8 9 10 →